March is #MyelomaActionMonth! Back at work after my CAR-T cellular therapy, and I’m attending a series of GenAI workshops for educators. Today I tried to make a superhero figure from my original blood smear. It needs some work, but I’m #MoreThanMyeloma, so I’ll get there.

Happy π day. Here's a pie chart

UMass Chan’s community engagement efforts celebrated with distinguished classification UMass Chan is one of 277 institutions nationwide to meet the criteria for the 2026 Carnegie Elective Classification for Community Engagement.

UMass Chan Medical School is one of 277 institutions—and one of just four medical schools—to meet the criteria for the 2026 Carnegie Elective Classification for Community Engagement. direc.to/oo8h

#CarnegieCE2026 #community #Worcester @aceducation.bsky.social @uofmass.bsky.social

How federal cuts are hurting research into pediatric brain cancer Confusion around federal research cuts and delays that began causing problems last year is continuing into 2026.

“Really what's at hand here is the future of health and science and technology in our country." - Rachael Sirianni, PhD, speaking to Here & Now about how delays in federal funding have affected her pediatric brain cancer research: direc.to/ooYx

#ResearchFunding @docsirianni.bsky.social @npr.org

Looking forward to participating in this forum about the great #myeloma studies coming out of ASH this month! So many reasons to be hopeful! #mmsm #IMFASH25 #ASH25

#ash25 Another potentially practice changing study presented by myeloma superstar Marivi Mateos - Ph3 of Tec-Dara in RR MM #mmsm 1/n

Grateful to join the #IMFASH25 Myeloma Voices team virtually while my immune system recovers from my recent CAR-T cellular therapy. I’m waving in the virtual screen during our hybrid team meeting! Everyone on our team provides a unique perspective on the #myeloma journey #mmsm #ASH25

The Fast Pace of Progress in Myeloma Treatment Practice Multiple myeloma patient and team member of the IMF Myeloma Voices at the American Society of Hematology (ASH) Annual Meeting & Exposition reports from the first day of ASH 2025.

My first blog on my #ASH25 experience with #IMFASH25 Myeloma Voices is now up! #Myeloma therapies continue to develop and expand at a rapid pace! #grateful #mmsm www.myeloma.org/blog/fast-pa...

Vincent Rajkumar: 20 Years, 20 FDA Approvals for Relapsed Myeloma - OncoDaily Vincent Rajkumar: 20 Years, 20 FDA Approvals for Relapsed Myeloma / cancer, FDA, multiple myeloma, Myeloma, OncoDaily, Oncology, Vincent Rajkumar

20 Years, 20 FDA Approvals for Relapsed Myeloma - Vincent Rajkumar

@vincentrk.bsky.social
@fda.gov

oncodaily.com/voices/fda-a...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDA #Myeloma #MM

An #ASHaiku -
I’m ready for ASH
A sweet kitty in my lap
Let the talks begin.
#IMFASH25 #ASH25 #mmsm

My #ASH25 #IMF25 started pack includes a comfy chair with a heating pad against my back and kitty in my lap trying to crowd out my laptop because this patient advocate will be attending virtually! 😊♥️😻

Myeloma Voices at ASH The International Myeloma Foundation brings myeloma support group leaders and patients to the annual meeting of the American Society of Hematology (ASH), an exciting convergence of over 30,000 health ...

I am so excited to be attending #ASH25 this weekend and reporting on new #myeloma therapies in the pipeline as part of the International Myeloma Foundation’s Myeloma Voices at ASH Team #IMFASH25. Myeloma friends, you can follow along here: www.myeloma.org/resources-su....

Don't want to miss this livestream on 12/8 broadcasting from the 2025 ASH meeting! IMF CMO Dr. Joseph Mikhael will be joined by support group leaders to share what’s most important to myeloma patients from the latest ASH research. https://www.facebook.com/events/837237505620824
#ASH25 #IMFASH25

Exposing the disease that tries to stay hidden, one beat at a time—it's the Flow to Know Myeloma. Get informed at knowmyeloma.org #FlowtoKnowMyeloma #KnowMyeloma #HealthHopeAndHipHop

Why a rare blood cancer has become a testing ground for cancer drug innovation A model of innovation

www.fastcompany.com/91388585/why...

Hello, Boston and central MA area friends! This month for Blood Cancer Awareness, you can #knowmyeloma by attending a community #myeloma workshop. Also, you’ll hear my husband and I talk about the patient/care partner dance of a busy family! ♥️💃🕺🏻♥️

September is blood cancer awareness month! #kNOwMyeloma

Hey that’s my better half in the middle! After my #myeloma diagnosis, we both took a major career leap. Now I teach the next generation of scientists and physicians and he develops new scientific instruments. Setting up shop at MBI has been the best decision for him. Basic science saves lives. 😊♥️

UMass Chan Chancellor Michael Collins to step down next year Dr. Michael Collins, the longest-serving chancellor of UMass Chan Medical School, will step down from his role leading the Worcester institution at the end of the 2025-2026 academic school year.

BREAKING: Dr. Michael Collins, the longest-serving chancellor of UMass Chan Medical School, will step down from his role leading the Worcester institution at the end of the 2025-2026 academic school year.

www.wbjournal.com/article/umas...

Congratulations to the McDougall, Wang and Silverman labs for their recent publication! The SCOPE is proud to help with your research @umasschan.bsky.social @cellpress.bsky.social #microscope #microscopy #covidresearch #UserHighlight

UMass Chan scientists discover process controlling cilia development Research by Sumeda Nandadasa, PhD, a scientist at UMass Chan, uncovers a molecular mechanism affecting ciliopathies such as Meckel-Gruber and Joubert syndromes and cystic kidney disease.

UMass Chan Medical School study explains dual functioning of Meckel-Gruber syndrome gene: direc.to/nS_j

Meckel-Gruber syndrome impacts child development due to mutations in genes responsible for cilia, which are essential for movement. As published in @natcomms.nature.com. @karenphd.bsky.social

Kicking off #RNATx2025 with our career workshop @UMassChan.bsky.social! Exploring careers for PhDs in academia, industry, and beyond the bench. We are excited to welcome our career panelists from all realms to discuss their career journeys as our trainees prepare for theirs.

PhD candidate Bradley Class receives NIH grant to study Louis-Bar syndrome PhD candidate Bradley Class has received a NIH grant to further his research on neuron mutations and ataxia-telangiectasia, a rare disease characterized by impaired motor function, dilated blood vesse...

PhD candidate Bradley Class has received a NIH fellowship to further his research into the correlation between neuron mutations and ataxia-telangiectasia, or Louis-Bar syndrome: direc.to/nT12

#RareDisease #research #NIH #PhD #PhDSky @bradclass.bsky.social @uofmass.bsky.social

Every machine in a Hospital that diagnoses your body without cutting you open is based on a principle of Physics, discovered by a Physicist who had no interest in Medicine.

If you think the world doesn’t need Basic Science, or that somehow Science has failed you, think again.

PhD candidate studies rare form of sarcoma PhD candidate Favour Akabogu has earned a scholarship and an award to continue research developing new therapies for GIST, a rare type of cancer.

PhD candidate Favour Akabogu is working to develop new therapies for a rare type of sarcoma called gastrointestinal stromal tumor (GIST), a tumor that develops throughout the gastrointestinal tract: direc.to/nQ_m

#StudentSpotlight #Research #PhD
@sarcomalab.bsky.social

The Price of Remission When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked ...

I have written many healthcare stories, but never before have I written about my own health. I decided to do so after learning one of my drugs costs nearly $1,000 a pill and just 25 cents to make. What I found was an incredible story of discovery and exploitation. www.propublica.org/article/revl...

Started my 3rd line of treatment in my 8 year multiple myeloma journey yesterday. None of these options would be available without all the basic science studies to understand cellular mechanisms. I’m fortunate that so many new #myeloma drugs have been approved in the last 10 years as a result.

And #grateful for my amazing all nurse care team today who answered all my questions, helped me navigate my care, and provided compassionate oncology care! 💜🩷 #ThankYouNurses #NationalNursesDay

Back in the infusion center starting my third line that includes a monoclonal antibody that stimulates my body’s natural killer cells to keep my #myeloma under control. Thank goodness for the downstream fruits of basic science research or I wouldn’t have this option! #mmsm Science saves lives! 💜🧫🧪🐁♥️

Federal cuts to National Institutes of Health could threaten medical progress YouTube video by 60 Minutes

The 60 minutes piece on the #NIH cuts and firings is well worth the watch. youtu.be/U8CcOAsyORM